StockData
Genmab A/S logo

Genmab A/S

GMABNasdaqPharmaceutical PreparationsAlso trades as GNMSF
Financials through fiscal 2025, year ended Dec 31, 2025Score 0/30
$50.97−0.99 (-1.91%)

Close on Nov 18, 2026

Genmab A/S Employees at Period-End (FTEs) by Quarter

Genmab A/S Employees at Period-End (FTEs): 3,244 in Q3 2026, up 21.0% from a year earlier. That is the highest of the 31 quarters on record here.

Latest, Q3 2026
3,244
Period ended Sep 30, 2026
Change on a year earlier
+21.0%
2,681 in Q3 2025
History
31 quarters
Since Q1 2019
Sources
23
Documents cited below

Where the Q3 2026 figure comes from

“|| Number of employees (FTE) at the end of the period | 3,244 | 2,681 | 3,244 | 2,681 | 3,029”

Source: Genmab Form 6-K — Q3 2026 Interim Report (Nine Months Ended Sep 30, 2026) ↗

Consolidated full-time equivalent employees at period-end across R&D, commercial, and administrative operations (includes ProfoundBio from Q2 2024 and Merus N.V. from Q4 2025).

quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedEmployees at Period-End (FTEs)Year on yearSource
Q3 2026Sep 30, 20263,244+21.0%Genmab Form 6-K — Q3 2026 Interim Report (Nine Months Ended Sep 30, 2026) ↗
Q2 2026Jun 30, 20263,119+18.2%Genmab Form 6-K — H1 / Q2 2026 Interim Report (Six Months Ended Jun 30, 2026) ↗
Q1 2026Mar 31, 20263,088+17.1%Genmab Form 6-K — Q1 2026 Interim Report (Three Months Ended Mar 31, 2026) ↗
Q4 2025Dec 31, 20253,029+12.9%Genmab Statutory Annual Report 2025 (Consolidated, ESRS & Parent Company FS, Form 20-F Ex.) ↗
Q3 2025Sep 30, 20252,681+1.7%Genmab Form 6-K — Q3 2025 Interim Report (Nine Months Ended Sep 30, 2025) ↗
Q2 2025Jun 30, 20252,639+4.5%Genmab Form 6-K — H1 / Q2 2025 Interim Report (Six Months Ended Jun 30, 2025) ↗
Q1 2025Mar 31, 20252,638+15.4%Genmab Form 6-K — Q1 2025 Interim Report (Three Months Ended Mar 31, 2025) ↗
Q4 2024Dec 31, 20242,682+21.7%Genmab Statutory Annual Report 2025 (Consolidated, ESRS & Parent Company FS, Form 20-F Ex.) ↗
Q3 2024Sep 30, 20242,635+23.6%Genmab Form 6-K — Q3 2024 Interim Report (Nine Months Ended Sep 30, 2024) ↗
Q2 2024Jun 30, 20242,526+25.4%Genmab Form 6-K — H1 / Q2 2024 Interim Report (Six Months Ended Jun 30, 2024) ↗
Q1 2024Mar 31, 20242,286+23.8%Genmab Form 6-K — Q1 2024 Interim Report (Three Months Ended Mar 31, 2024) ↗
Q4 2023Dec 31, 20232,204+32.8%Genmab Statutory Annual Report 2025 (Consolidated, ESRS & Parent Company FS, Form 20-F Ex.) ↗
Q3 2023Sep 30, 20232,132+36.7%Genmab Form 6-K — Q3 2023 Interim Report (Nine Months Ended Sep 30, 2023) ↗
Q2 2023Jun 30, 20232,015+39.4%Genmab Form 6-K — H1 / Q2 2023 Interim Report (Six Months Ended Jun 30, 2023) ↗
Q1 2023Mar 31, 20231,846+41.0%Genmab Form 6-K — Q1 2023 Interim Report (Three Months Ended Mar 31, 2023) ↗
Q4 2022Dec 31, 20221,660+37.0%Genmab Statutory Annual Report 2025 (Consolidated, ESRS & Parent Company FS, Form 20-F Ex.) ↗

Breakdown

What makes up employees at Period-End (FTEs)

Cite this data

StockData. (2026). Genmab A/S Employees at Period-End (FTEs), quarterly Q1 2019–Q3 2026 [Data set]. Compiled from Genmab A/S SEC filings and investor materials. https://stockdatahq.com/stocks/gmab/kpis/fte-end

See every metric in the Genmab A/S KPI table. Data updated Nov 11, 2026.

See a number that looks wrong?